Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Prognosis After AlloHCT Determined by Disease Risk Index
Biol Blood Marrow Transplant; ePub 2017 May 15; He, et al
Disease risk index (DRI) can predict post-transplant relapse, treatment failure, and mortality in elderly people with advanced hematologic malignancies receiving reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), according to a study involving 196 individuals.
Participants received transplants from either adult related and unrelated donors (n=100) or umbilical cord blood (n=96). Among the results:
- 6% were categorized as low risk; three-fourths intermediate risk; and 19% high risk per DRI.
- 2-year overall survival was 47% (52% for low and intermediate risk; 29% for high risk).
- 2-year disease-free survival was 39% (44% for low and intermediate risk; 21% for high risk).
- Relapse incidence was 30% (26% for low and intermediate risk; 44% for high risk).
- Overall treatment-related mortality at 2 years was 29%.
He F, Cao Q, Lazaryan A, et al. Allogeneic hematopoietic cell transplantation for older patients: Prognosis determined by disease risk index. [Published online ahead of print May 15, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.05.012.